Celldex Therapeutics, Inc. share price logo

Celldex Therapeutics, Inc. Share Price

NASDAQ: CLDX

Mid Cap

$30.89

+0.86

(+2.86%)

as on

Celldex Therapeutics, Inc. Stock Performance

as on March 21, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $29.99
    $31.85
    downward going graph

    2.91%

    Downside

    3.11%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $14.40
    $31.99
    downward going graph

    53.38%

    Downside

    3.56%

    Upside

    downward going graph

Celldex Therapeutics, Inc. share price movements today

Previous Close
$30.03
Open
$30.26
Volume
1.2M
Day's Low - High
$29.99 - $31.85
52 Week Low - High
$14.40 - $31.99

Celldex Therapeutics, Inc. Historical Returns

1 Month Return
+ 34.23 %
3 Month Return
+ 20.7 %
1 Year Return
+ 57.33 %
3 Year Return
-20.99 %
5 Year Return
+ 23.16 %

Celldex Therapeutics, Inc. Stock Fundamentals & Key Indicators

Check Celldex Therapeutics, Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$2.1B

EPS (TTM)

-4.7746

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-17.62

Industry PE ratio

7.891681415929203

PEG Ratio

0

EBITDA

-284.0M

Revenue (TTM)

1.5M

Profit Margin

0.00%

Return On Equity TTM

-40.62%

Celldex Therapeutics, Inc. Stock Valuation

Track how Celldex Therapeutics, Inc. P/E has moved over time to understand its valuation trends.

Celldex Therapeutics, Inc. in the last 5 years

  • Overview

  • Trends

Lowest (-26.66x)

September 30, 2021

Today (-17.62x)

March 21, 2026

Industry (7.89x)

March 21, 2026

Highest (-6.47x)

June 30, 2025

LowHigh

Today’s Price to Earnings Ratio: -17.62x

Celldex Therapeutics, Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Celldex Therapeutics, Inc. with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Celldex Therapeutics, Inc. image
Celldex Therapeutics, Inc.
BUY$2.1B23.16%-17.620.00%
Alnylam Pharmaceuticals, Inc. image
Alnylam Pharmaceuticals, Inc.
BUY$41.3B116.54%133.528.45%
Vertex Pharmaceuticals Incorporated image
Vertex Pharmaceuticals Incorporated
BUY$116.3B110.08%29.9432.94%
Beone Medicines Ltd image
Beone Medicines Ltd
NA$32.5BNA114.935.37%
Regeneron Pharmaceuticals, Inc. image
Regeneron Pharmaceuticals, Inc.
BUY$78.0B54.71%17.831.41%

Stock Returns calculator for Celldex Therapeutics, Inc. Stock including INR - Dollar returns

The Celldex Therapeutics, Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Celldex Therapeutics, Inc. investment value today

Current value as on today

₹1,66,726

Returns

₹66,726

(+66.73%)

Returns from Celldex Therapeutics, Inc. Stock

₹57,281 (+57.28%)

Dollar Returns*

₹9,445 (+9.44%)

Analyst Recommendation on Celldex Therapeutics, Inc. Stock

Based on 14 analysts

BUY

85.71%

Buy

14.29%

Hold

0.00%

Sell

Based on 14 analysts, 85.71% of analysts recommend a 'BUY' rating for Celldex Therapeutics, Inc.. Average target price of $55.07

Celldex Therapeutics, Inc. Share Price Target

Get share price movements and forecasts by analysts on Celldex Therapeutics, Inc..

What analysts predicted

43.91%UPSIDE

Target Price

$55.07

Current Price

$30.89

Analyzed by

14 Analysts

Target

$55.07

Celldex Therapeutics, Inc. target price $55.07, a slight upside of 43.91% compared to current price of $30.89. According to 14 analysts rating.

Celldex Therapeutics, Inc. Stock’s Investor Sentiment and Interest

Search interest for Celldex Therapeutics, Inc. Stock has increased by 88% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:88% versus previous 30 day period

Celldex Therapeutics, Inc. Quarterly Profit & Loss

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Total Revenue
1
4
0
2
3
1
0
0
-
0
Gross Profit
0
-26
0
1
3
0
0
0
-62
0
Operating Income
-41
-47
-40
-46
-52
-56
-62
-63
-73
-87
EBITDA
-40
-34
-39
-45
-51
-55
-61
-62
-72
-80
Interest Expense
-
3
-
-
-
-
-
-
-
-
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-38
-43
-32
-35
-42
-47
-53
-56
-67
-81
Income Tax Expense
-2
13
0
-
-
-
-
-
-
-
Net Income
-38
-43
-32
-35
-42
-47
-53
-56
-67
-81
Net Profit Margin
-2522.08%
-1048.32%
-21030.77%
-1434.83%
-1319.99%
-4007.83%
-7740.43%
-7753.42%
0.00%
-108480.00%

Celldex Therapeutics, Inc. Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
6
12
9
3
7
4
2
6
7
1
Gross Profit
-95
-83
-56
-39
-35
-48
-79
-111
-156
1
Operating Income
-132
-121
-156
-55
-63
-71
-115
-154
-195
-287
EBITDA
-124
-104
-72
-49
-45
-66
-104
-139
-191
-255
Interest Expense
-
15
151
-
18
0
2
-
-
-
Depreciation
-
5
3
4
3
3
2
2
3
3
Income Before Tax
-128
-117
-151
-50
-60
-70
-112
-141
-157
-258
Income Tax Expense
-8
-24
0
0
-1
0
10
2
-157
-
Net Income
-128
-93
-151
-50
-59
-70
-112
-141
-157
-258
Net Profit Margin
-1894.05%
-730.06%
-1585.07%
-1423.96%
-805.88%
-1516.04%
-4765.59%
-2054.76%
-2248.76%
-17253.33%

Celldex Therapeutics, Inc. Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Net Income
-43
-32
-35
-42
-47
-53
-56
-67
-81
Operating Cash Flow
-32
-40
-29
-55
-32
-54
-44
-48
-63
Investing Cash Flow
-171
-315
-46
47
24
42
49
60
55
Financing Cash Flow
217
436
3
1
0
0
0
0
1
Change in Cash
13
80
-72
-6
-8
-11
5
12
-7

Celldex Therapeutics, Inc. Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-93
-151
-50
-59
-70
-112
-141
-157
-258
Operating Cash Flow
-99
-75
-46
-40
-60
-103
-107
-157
-210
Investing Cash Flow
46
29
17
-98
-216
89
-105
-290
209
Financing Cash Flow
51
29
16
171
272
4
218
441
2
Change in Cash
-2
-15
-13
32
-4
-9
5
-6
0

Global Institutional Holdings in Celldex Therapeutics, Inc.

Funds
Holdings
FMR Inc
7.37%
State Street Corp
4.27%
Vestal Point Capital LP
1.75%
Point72 Asset Management, L.P.
5.85%
T. Rowe Price Associates, Inc.
3.58%
See all

Celldex Therapeutics, Inc. News & Key Events

  • img

    Today's Timeline - 09 September

    Tue, 06:31 PM

    -

    Celldex Therapeutics to present at Morgan Stanley Healthcare Conference today at 3:20 PM ET.

Insights on Celldex Therapeutics, Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 7 days, CLDX stock has moved up by 4.7%

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, CLDX has outperformed top 5 stocks with highest market-cap in its industry

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Celldex Therapeutics, Inc. has experienced a drawdown of -14.9%, however Alnylam Pharmaceuticals, Inc. resisted the overall trend and outperformed by 12.4%

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 2 quarters, 730.0K → 75.0K (in $), with an average decrease of 89.7% per quarter

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 8 quarters, -32.80M → -81.36M (in $), with an average decrease of 14.0% per quarter

About Celldex Therapeutics, Inc.

celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. celldex therapeutics (nasdaq: cldx) was founded based on a fundamental scientific belief that harnessing the power of the immune system would break significant barriers in drug development for a host of devastating diseases. the company's pipeline is comprised of therapeutic antibodies, antibody drug conjugates, immune system modulators and vaccines that we believe have a higher probability of success because they are targeted to specific patient populations with high unmet medical need whose diseases express specific markers, including many underserved or completely un-served orphan indications. this has created a leading pipeline in im
OrganisationCelldex Therapeutics, Inc.
HeadquartersPerryville III Building, Hampton, NJ, United States, 08827
IndustryHealth Technology
CEOMr. Anthony S. Marucci M.B.A.
E-voting on sharesClick here to vote

Key Management of Celldex Therapeutics, Inc.

Name

Title

Prof. Joseph P. Schlessinger Ph.D.

Co-Founder & Member of Scientific Advisory Board

Ms. Sarah Cavanaugh

Senior Vice President of Corporate Affairs & Administration

Mr. Freddy A. Jimenez Esq.

Senior VP & General Counsel

Dr. Ronald A. Pepin Ph.D.

Chief Business Officer & Senior VP

Dr. Tibor Keler Ph.D.

Founder, Chief Scientific Officer & Executive VP

Mr. Sam Martin CPA

Senior VP, CFO, Secretary & Treasurer

Dr. Margo Heath-Chiozzi M.D.

Senior Vice President of Regulatory Affairs

Dr. Diane C. Young M.D.

Senior VP & Chief Medical Officer

Mr. Anthony S. Marucci M.B.A.

Founder, President, CEO & Director

Ms. Elizabeth Crowley

Chief Product Development Officer & Senior VP

FAQs

What is Celldex Therapeutics, Inc. share price today?

Celldex Therapeutics, Inc. share price today is $30.89 as on at the close of the market. Celldex Therapeutics, Inc. share today touched a day high of $31.85 and a low of $29.99.

What is the 52 week high and 52 week low for Celldex Therapeutics, Inc. share?

Celldex Therapeutics, Inc. share touched a 52 week high of $31.99 on and a 52 week low of $14.4 on . Celldex Therapeutics, Inc. stock price today i.e. is closed at $30.89,which is 3.44% down from its 52 week high and 114.51% up from its 52 week low.

What is Celldex Therapeutics, Inc.'s market capitalisation today?

Celldex Therapeutics, Inc. market capitalisation is $0.00T as on .

How to invest in Celldex Therapeutics, Inc. Stock (CLDX) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Celldex Therapeutics, Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Celldex Therapeutics, Inc. Shares that will get you 0.0486 shares as per Celldex Therapeutics, Inc. share price of $30.89 per share as on March 21, 2026 at 1:29 am IST.

What is the minimum amount required to buy Celldex Therapeutics, Inc. Stock (CLDX) from India?

Indian investors can start investing in Celldex Therapeutics, Inc. (CLDX) shares with as little as ₹93.652 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹936.52 in Celldex Therapeutics, Inc. stock (as per the Rupee-Dollar exchange rate as on ). Based on Celldex Therapeutics, Inc. share’s latest price of $30.89 as on March 21, 2026 at 1:29 am IST, you will get 0.3237 shares of Celldex Therapeutics, Inc.. Learn more about fractional shares .

What are the returns that Celldex Therapeutics, Inc. has given to Indian investors in the last 5 years?

Celldex Therapeutics, Inc. stock has given 23.16% share price returns and 28.37% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?